{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T03:00:11Z","timestamp":1770433211430,"version":"3.49.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1016\/j.clinthera.2007.04.016","type":"journal-article","created":{"date-parts":[[2007,7,6]],"date-time":"2007-07-06T11:20:34Z","timestamp":1183720834000},"page":"617-625","source":"Crossref","is-referenced-by-count":31,"title":["A phase i, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults"],"prefix":"10.1016","volume":"29","author":[{"given":"Dennis","family":"Swearingen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Pennick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Shojaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Lyne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Fiske","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2007.04.016_bib1","first-page":"842","article-title":"Mental health in the United States. Prevalence of diagnosis and medication treatment for attention-deficit\/ hyperactivity disorder-United States, 2003","volume":"54","author":"Centers for Disease Control and Prevention (CDC)","year":"2005","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"10.1016\/j.clinthera.2007.04.016_bib2","series-title":"Evidence based clinical practice guidelines: Outpatient evaluation and management of attention deficit\/hyperactivity disorder","author":"Cincinnati Children's Hospital Medical Center","year":"2004"},{"key":"10.1016\/j.clinthera.2007.04.016_bib3","series-title":"Fourth Edition, Text Revision (DSM-1V-TR)","author":"Diagnostic and Statistical Manual of Mental Disorders","year":"2000"},{"key":"10.1016\/j.clinthera.2007.04.016_bib4","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1542\/peds.108.4.1033","article-title":"Clinical practice guideline: Treatment of the school-aged child with attention-deficit\/hyperactivity disorder","volume":"108","author":"American Academy of Pediatrics Subcommittee on Attention-Deficit\/Hyperactivity Disorder and Committee on Quality Improvement","year":"2001","journal-title":"Pediatrics"},{"key":"10.1016\/j.clinthera.2007.04.016_bib5","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/archpsyc.56.12.1073","article-title":"A 14-month randomized clinical trial of treatment strategies for attentiondeficit\/hyperactivity disorder. Multimodal Treatment Study of Children with ADHD","volume":"56","year":"1999","journal-title":"Arch Gen Psychiatry."},{"key":"10.1016\/j.clinthera.2007.04.016_bib6","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1542\/peds.113.4.754","article-title":"National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-Month outcomes of treatment strategies for attentiondeficit\/hyperactivity disorder","volume":"113","year":"2004","journal-title":"Pediatrics"},{"issue":"Suppl 4","key":"10.1016\/j.clinthera.2007.04.016_bib7","first-page":"S117","article-title":"New options in the pharmacological management ofattentiondeficit\/hyperactivity disorder","volume":"10","author":"Olfson","year":"2004","journal-title":"Am J Manag Care."},{"key":"10.1016\/j.clinthera.2007.04.016_bib8","first-page":"262","article-title":"Nonstimulanttherapies for attention-deficit hyperactivity disorder (ADHD) in children and adults","volume":"6","author":"Waxmonskyj","year":"2005","journal-title":"Essent Psychopharmacol"},{"key":"10.1016\/j.clinthera.2007.04.016_bib9","series-title":"US Food and Drug Administration. Drugs of abuse. Chapter 5 Stimulants","year":"2005"},{"key":"10.1016\/j.clinthera.2007.04.016_bib10","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.biopsych.2004.08.019","article-title":"Neurobiology of executive functions: Catecholamine influences on prefrontal cortical functions","volume":"57","author":"Arnsten","year":"2005","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.clinthera.2007.04.016_bib11","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.biopsych.2004.08.026","article-title":"The neuropsychopharmacology of attention-deficit\/hyperactivity disorder","volume":"57","author":"Pliszka","year":"2005","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.clinthera.2007.04.016_bib12","doi-asserted-by":"crossref","first-page":"8771","DOI":"10.1523\/JNEUROSCI.22-19-08771.2002","article-title":"Mutation of the \u03b12 adrenoceptor impairs working memory perfor mance and annuls cognitive enhancement by guanfacine","volume":"22","author":"Franowicz","year":"2002","journal-title":"J Neurosci."},{"key":"10.1016\/j.clinthera.2007.04.016_bib13","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1001\/archpsyc.1996.01830050084013","article-title":"The contributionof \u03b12 noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder","volume":"53","author":"Arnsten","year":"1996","journal-title":"Arch Gen Psychiatry."},{"key":"10.1016\/j.clinthera.2007.04.016_bib14","doi-asserted-by":"crossref","first-page":"7264","DOI":"10.1523\/JNEUROSCI.22-16-07264.2002","article-title":"Exposure of adolescent rats to oral methylphenidate prefrontal effects on extracellu lar norepinephrine and absence of sensitization and cross-sensitization to methamphetamine","volume":"22","author":"Kuczenski","year":"2002","journal-title":"J Neurosci."},{"key":"10.1016\/j.clinthera.2007.04.016_bib15","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1744-9081-1-2","article-title":"Methylphenidate improves prefrontal cortical cognitive function through \u03b1-adrenoreceptor and dopamine D1 receptor actions: Relevance to therapeutic effects in attention deficit hyperactivity disorder","volume":"1","author":"Arnsten","year":"2005","journal-title":"Behav Brain Funct."},{"key":"10.1016\/j.clinthera.2007.04.016_bib16","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1089\/cap.1995.5.215","article-title":"Guanfacine for treatment of attention-deficit hyperactivity disorder in boys","volume":"5","author":"Horrigan","year":"1995","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"10.1016\/j.clinthera.2007.04.016_bib17","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/00004583-199501000-00013","article-title":"An open trial of guanfacine in the treatment of attention-deficit hyper activity disorder","volume":"34","author":"Hunt","year":"1995","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.clinthera.2007.04.016_bib18","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1176\/appi.ajp.158.7.1067","article-title":"A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder","volume":"158","author":"Scahill","year":"2001","journal-title":"Am J Psychiatry."},{"key":"10.1016\/j.clinthera.2007.04.016_bib19","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00004714-200104000-00015","article-title":"Comparing guanfacine and dextroamphetamine for the treatment of adult attention deficit\/hyperactivity disorder","volume":"21","author":"Taylor","year":"2001","journal-title":"J Clin Psychopharmacol."},{"key":"10.1016\/j.clinthera.2007.04.016_bib20","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1097\/00004583-199509000-00010","article-title":"Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: Preliminary clinical experience","volume":"34","author":"Chappell","year":"1995","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"key":"10.1016\/j.clinthera.2007.04.016_bib21","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1161\/01.CIR.92.5.1068","article-title":"Nifedipine and mortality. Grave defects in the dossier","volume":"92","author":"Opie","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2007.04.016_bib22","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1001\/jama.261.22.3273","article-title":"How often is medication taken as prescribed? A novel assessment technique","volume":"261","author":"Cramer","year":"1989","journal-title":"JAMA"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291807001166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291807001166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T04:49:02Z","timestamp":1556599742000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291807001166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["S0149291807001166"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2007.04.016","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}